This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00564161
First received: November 25, 2007
Last updated: September 1, 2016
Last verified: November 2007
  Purpose
We hypothesize that misexpression of vascular endothelial growth factor (VEGF) in the Cerebrospinal fluid of preterm infants can be used as a biomarker to predict the risk for developing white matter damage.

Condition
Preterm Infants With White Matter Damage Preterm Infants Developing Normally

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants

Further study details as provided by Hadassah Medical Organization:

Biospecimen Retention:   Samples Without DNA
CSF.

Enrollment: 0
Study Start Date: January 2008
Estimated Study Completion Date: January 2009

  Eligibility

Ages Eligible for Study:   25 Weeks to 40 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
preterm infants.
Criteria

Inclusion Criteria:

  • Preterm infants undergoing lumbar puncture.

Exclusion Criteria:

  • Preterm with IVH or known infection or meningitis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00564161

Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Principal Investigator: Talya Dor, MD Hadassah Medical Organization
  More Information

ClinicalTrials.gov Identifier: NCT00564161     History of Changes
Other Study ID Numbers: 606060-HMO-CTIL
Study First Received: November 25, 2007
Last Updated: September 1, 2016

Additional relevant MeSH terms:
Premature Birth
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications

ClinicalTrials.gov processed this record on June 23, 2017